Medicenna Therapeutics Corp.

About Medicenna Therapeutics Corp.

Medicenna is a clinical stage immunotherapy company focused on using directed evolution to create engineered interleukins called Superkines. These therapies modulate, fine-tune, or amplify the immune system to combat challenging diseases such as cancer, autoimmune, and neuroinflammatory conditions, aiming to inspire hope in patients with unmet needs.

Products & Services

Superkines:Engineered interleukins designed to improve specificity, function, and safety, used to modulate or amplify the immune system for treating cancer, autoimmune, and neuroinflammatory diseases.

MDNA11:A specific therapy or product candidate in Medicenna's pipeline, focused on immunotherapy.

BiSKITs:A product or technology in the pipeline, likely related to innovative immunotherapy solutions.

Specialties

Engineered Interleukins (Superkines) Immunotherapy Cancer Treatment Autoimmune Diseases Neuroinflammatory Diseases Interleukin-2 (IL-2), IL-4, and IL-13 Super-Agonists and Antagonists

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Share Purchase T: - FT: Share Purchase	A: 35520 MR: - FA: $35,520 FAN: 35520	D: 2025-12-15 FD: 2025-12-15	1 investors
2	RT: Private Placement T: - FT: Private Placement	A: 20000000 MR: - FA: CA$20 million FAN: 20000000	D: 2024-04-30 FD: 2024-04-30	1 investors
3	RT: Private Placement T: - FT: Private Placement	A: 20000000 MR: - FA: 20 million FAN: 20000000	D: 2024-04-26 FD: 2024-04-26	1 investors
4	RT: Warrant Extension T: - FT: Warrant Extension	A: 2710041 MR: - FA: Potential from exercise of 1,549,052 warrants at $1.75 each FAN: 2710041	D: 2023-07-05 FD: 2023-07-05	-
5	RT: Share Purchase T: - FT: Share Purchase	A: 27600 MR: - FA: $27,600 FAN: 27600	D: 2023-02-21 FD: 2023-02-21	1 investors
6	RT: At-the-Market Offering T: - FT: At-the-Market Offering	A: 10000000 MR: - FA: US$10 million FAN: 10000000	D: 2023-02-17 FD: 2023-02-17	1 investors

Share Purchase Latest

2025-12-15

$36K

1 investor (Pro only)

Private Placement 2024-04-30

$20.0M

Private Placement 2024-04-26

$20.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sergio Quezada

Chairman

B

Burkhard Becher

Professor at the University of Zurich and Chair of the Institute of Experimental Immunology

D

David Mooney

Robert Pinkas Family Professor of Bioengineering

W

William Redmond

Director of the Immune Monitoring Laboratory and Full Member at the Earle A. Chiles Research Institute

J

James Allison

Nobel Laureate

R

Robert Langer

View 16 more team members with Pro

Unlock Full Team Directory

Recent News